Skip to main content
Quest Diagnostics

Risk Estimation of Severe COVID-19 Based on Initial Biomarker Assessment Across Racial and Ethnic Groups

Risk estimation of severe COVID-19 based on initial biomarker assessment across racial and ethnic groups

Authors: Kroll MH, Bi C, Salm AE, Szymanski J, Goldstein DY, Wolgast LR, Rosenblatt G, Fox AS, Kapoor H

Arch Pathol Lab Med. 2023 Jun 20. doi: 10.5858/arpa.2023-0039-SA. Online ahead of print.

Specialties: Infectious disease, COVID-19

Related content

Publication
Disparities in SARS CoV 2 Positivity Rates Associations with Race and Ethnicity
Conference Presentation
Laboratory Use of Race, Ethnicity, Ancestry: A Focus on Diagnostic Testing
Publication
Association of ABO Rh with SARS CoV 2 positivity
Test FAQ
SARS CoV 2 Antibody Testing
Publication
Assessment of the Association of Vitamin D Level With SARS CoV 2 Seropositivity Among Working Age Adults

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.